Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

Wang, Eric, Mi, Xiaoli, Thompson, Meghan C., Montoya, Skye, Notti, Ryan Q., Afaghani, Jumana, Durham, Benjamin H., Penson, Alex +27 more·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2114110

Cited by (272)

Items 101–200 of 272

Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK
Ernest Awoonor‐Williams, Abd Al‐Aziz A. Abu‐Saleh · 2024 · The Journal of Physical Chemistry B
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma
Syed Ibrahim, Nghia Pham, Aarushi Sahni, Samantha Sekeres, Allison Cool, Justin M. Taylor, Catherine Callaghan Coombs · 2025 · Future Oncology
Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)
Florence Nguyen‐Khac, Zsófia Balogh, Jasmine Chauzeix, Lauren Véronèse, Élise Chapiro · 2023 · Current Research in Translational Medicine
Unraveling MCL biology to understand resistance and identify vulnerabilities
Clémentine Sarkozy, Benoît Tessoulin, David Chiron · 2024 · Blood
Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
Hana Dostálová, Vladimı́r Kryštof · 2024 · Hematological Oncology
Predicting Resistance to Small Molecule Kinase Inhibitors
Anu Nagarajan, Katherine Amberg-Johnson, Evan Paull, Kunling Huang, Phani Ghanakota, Asela Chandrasinghe, Jackson Chief Elk, Jared M. Sampson, Lingle Wang, Robert Abel et al. · 2025 · Journal of Chemical Information and Modeling
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
Olivier Tournilhac, Michel van Gelder, Dirk‐Jan Eikema, Nienke Zinger, Peter Dreger, Martin Bornhäuser, Vladan Vučinić, Christof Scheid, Jan J. Cornelissen, Thomas A. Schroeder et al. · 2023 · Bone Marrow Transplantation
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Raji E. Joseph, Thomas E. Wales, Sandrine Jayne, Robert G. Britton, D. Bruce Fulton, John R. Engen, Martin J.S. Dyer, Amy Hamilton Andreotti · 2024 · eLife
Conditional requirement for dimerization of the membrane-binding module for BTK signaling in lymphocyte cell lines
Timothy J. Eisen, Sam Ghaffari-Kashani, Chien‐Lun Hung, Jay T. Groves, Arthur Weiss, John Kuriyan · 2025 · Science Signaling
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Zahraa Qusairy, Miran Rada · 2025 · Kinases and Phosphatases
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders
Andrea Duminuco, Paola De Luca, Gaia Stanzione, Laura Anastasia Caruso, Giulio Lavenia, Salvatore Scarso, Bruno Garibaldi, Fanny Erika Palumbo, Calogero Vetro, Giuseppe A. Palumbo · 2026 · Biomolecules
Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era
María Del Mar Sánchez Suárez, Alicia Martín Roldán, Carolina Alarcón-Payer, Miguel Ángel Rodríguez-Gil, Jaime Eduardo Poquet-Jornet, José Manuel Puerta, Alberto Jiménez Morales · 2023 · Pharmaceutics
Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review
Prioty Islam · 2023 · Current Treatment Options in Oncology
Trends and hotspots for European Journal of Medicinal Chemistry: A bibliometric study
Heng Zhang, Yunfan Gao, Guangcheng Fu, Junzhong Liu, Qingcai Jiao · 2022 · European Journal of Medicinal Chemistry
Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy
Gruessner, Christine, Wiestner, Adrian, Sun, Clare · 2025 · Leukemia & Lymphoma
LC-MS/MS characterization of pirtobrutinib impurities and product degradation: stability studies
Modachakanahally K. Pavithra, G. Chaya, Hemavathi Nagaraju Deepakumari, Hosakere Doddarevanna Revanasiddappa, Salah Jasim Mohammed, Hasan Sh. Majdi, Abdullah H. Alsabhan, Shareefraza J. Ukkund · 2024 · RSC Advances
Research progress on gene mutations and drug resistance in leukemia
Xiangyu Ma, Jiamin Xu, Yanan Wang, Joshua S. Fleishman, Hao Bing, Bin Yu, Yanming Li, Letao Bo, Shaolong Zhang, Zhe‐Sheng Chen et al. · 2024 · Drug Resistance Updates
Comprehensive Characterization of Bruton’s Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures
Antonia C. Darragh, Andrew M. Hanna, Justin Lipner, Alastair J. King, Nicole B. Servant, Mirza Jahic · 2025 · ACS Pharmacology & Translational Science
Recent advances in phototherapy-based nanomedicine of lymphoma
Jiaqing Huang, Yingying Zhang, Huihui Jin, Feng Yin, Xiangmin Tong, Lichen Ji, Yu Cai · 2025 · Materials Today Bio
PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications
Ping Jiang, Mingcong Wang, Chengzhe Zhang, Xiaopeng Li, Zhi qiang Wang, Yajuan Guo, Juhua Zhang, Wei Yan, Xiaobing Xi · 2026 · Journal of Translational Medicine
Real-world management of targeted therapies in chronic lymphocytic leukemia
Taylor Mai Weis, Jillian Gutierrez, Charlene C. Kabel, Amber C. King, Ryan J. Daley, Sarah E. Stump · 2022 · Journal of Oncology Pharmacy Practice
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?
Andrea Visentin, Marco Puthenparampil, Chiara Briani · 2023 · Expert Opinion on Investigational Drugs
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas
Peiran Song, Zhipeng Wan, Gege Huang, Zilan Song, Tao Zhang, Linjiang Tong, Yan Fang, Haotian Tang, Yu Xue, Zhengsheng Zhan et al. · 2024 · Acta Pharmacologica Sinica
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment
Annalisa Arcari, Lucia Morello, Elena Borotti, Elena Ronda, Rossi Angela, Daniele Vallisa · 2024 · Cancers
The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma
Zhao, Chuanyi, Miao, Daojia, Tan, Diaoyi, Shi, Jian, Lv, Qingyang, Xiong, Zhiyong, Zhang, Xiaoping · 2024 · Frontiers in Bioscience-Landmark
Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL
Ruowen Sun, Yanchao Yang, Bin Zhang, Jiayuan Chen, Ye Wang, Zehui Jiang, Linlin Zhang, Milad Ashrafizadeh, Gautam Sethi, Jing Shen et al. · 2025 · Materials Today Bio
Exploring pocket-aware inhibitors of BTK kinase by generative deep learning, molecular docking, and molecular dynamics simulations
Liting Zheng, Kun Qian, Jun Zhang, Meng-Ting Liu, Yi Li, Li-Quan Yang · 2025 · RSC Advances
Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials
Mário Sousa‐Pimenta, Ângelo Martins, José Mariz, Pedro Berraondo · 2023 · Frontiers in Immunology
Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia
Ilaria Del Giudice, Irene Della Starza, Filomena De Falco, Gianluca Gaïdano, Paolo Sportoletti · 2024 · Cancers
Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia
Bruce D. Cheson, Jeff Porter Sharman · 2024 · JCO Oncology Practice
Synthetic routes and clinical application of new drugs approved by EMA during 2023
Yu Xia, Qingqing Chen, Henan Liu, Yuan Chi, Ying Zhu, Lishen Shan, Bing Dai, Lin Wu, Xiaobao Shi · 2024 · European Journal of Medicinal Chemistry
In Silico Study and Validation of Natural Compounds Derived from Macleaya cordata as a Potent Inhibitor for BTK
Ayobami Fidelix, Tomilola Victor Akingbade, Jatin Jangra, Babatunde A Olabuntu, Olutola Adeyemo, Juwon Akingbade · 2025 · Medinformatics
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny
Giorgio Minotti, Massimiliano Camilli, Emanuela Salvatorelli, Pierantonio Menna · 2025 · British Journal of Pharmacology
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia
Brian T. Grainger, Philip A. Thompson, Chan Yoon Cheah · 2025 · Blood
Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL: a systematic review and meta-analysis
Mohammad Amin Karimi · 2025 · American Journal of Blood Research
Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors
Dandan Zhang, Jie Zhao, Guiqing Xu, Yue Wang, Yang Li, Hanxiao Ren, Jiajun Geng, Yu Du, Chenchen Zhang, Huayan Yang et al. · 2025 · Journal of Medicinal Chemistry
Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges
Yao Wang, Yaping Zhang, Jiaqi Liu, Yongning Jiang, Jianyong Li, Wenyu Shi · 2025 · Annals of Hematology
BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?
Sai Prasad Desikan, Sangeetha Venugopal, Alessandra Ferrajoli · 2022 · Expert Review of Hematology
Synthesis and application of small molecules approved for the treatment of lymphoma
Yuanyuan Guo, Jingyi Zhang, Jinfeng Sun, Peng Nie, Hua Gao · 2023 · European Journal of Medicinal Chemistry
A Workflow Combining Machine Learning with Molecular Simulations Uncovers Potential Dual-Target Inhibitors against BTK and JAK3
Lu Liu, Risong Na, Lianjuan Yang, Jixiang Liu, Yingjia Tan, Xi Zhao, Xuri Huang, Xuecheng Chen · 2023 · Molecules
Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level
Ramón García‐Sánz, María García‐Álvarez, Alejandro Medina, Elham Askari, Verónica González‐Calle, María Casanova, Igor de la Torre-Loizaga, Fernando Escalante, Miguel Bastos, Abelardo Bárez et al. · 2023 · Disease Models & Mechanisms
Advances in protein kinase drug discovery through targeting gatekeeper mutations
Jing Guo, Yang Zhou, Xiaoyun Lu · 2023 · Expert Opinion on Drug Discovery
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
Reema K. Tawfiq, Jithma P. Abeykoon, Prashant Kapoor · 2024 · Current Hematologic Malignancy Reports
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib
Burcu Aslan, Ganiraju C. Manyam, LaKesla R. Iles, Shady I. Tantawy, Sai Prasad Desikan, William G. Wierda, Varsha V. Gandhi · 2024 · Blood Advances
Comparison of differences in transcriptional and genetic profiles between intra-central nervous system and extra-central nervous system large B-cell lymphoma
Shu Wang, Hong Chen, Bo Dai, Kang Zheng, Jiajun Zheng, Yuqi Zhu, Yan Yuan, Tianling Ding, Qian Wang, Liqian Xie et al. · 2024 · Neoplasia
Computational insights into mutation-induced binding changes in Bruton’s Tyrosine Kinase with non-covalent inhibitors
Justice Josiah Mallen, Shilpa Sharma, Md. Nazmul Hasan, Arjun Saha · 2025 · Journal of Biomolecular Structure and Dynamics
Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment
Pratik V. Shah, Douglas Edward Gladstone · 2025 · Current Treatment Options in Oncology
Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer
Wei Peng Yong, Shu Zhang, Zhoudong Zhang, Zhihao Li, Yu Qin, Xiaofei Qi, Dong Wang, Yu‐Juan Zhang, Jianguo Li, Zhiyong Liu et al. · 2025 · Journal of Medicinal Chemistry
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)
Ze-Xi Cui, Sheng-Xin Yao, Yue-Xi Zhang, Huiyu Lu, Li‐Ping Sun, Lei Shi · 2025 · Expert Opinion on Therapeutic Patents
Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy
Samantha Sekeres, Erica N. Lamkin, Eduardo Bravo, Allison Cool, Justin Taylor · 2025 · Genes
Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways
Xinyu Dong, Shujun Tang, Miaohong Chen, Qiuni Chen, Yifan Wang, Yuye Shi, Yuan Deng, Yue Chen, Zhengmei He, Liang Yu et al. · 2026 · Annals of Hematology
PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia
Chunfang Kong, Mei Wu, Qilin Lu, Bo Ke, Jianhui Xie, Anna Li · 2024 · Leukemia Research
A high-throughput assay platform to discover small molecule activators of the phospholipase PLC-γ2 to treat Alzheimer's disease
Adam J. Carr, Nicole Hajicek, Andy Po‐Yi Tsai, Padam P. Acharya, P. Brian Hardy, Emma G. Meyer, Tony Wyss‐Coray, Kenneth H. Pearce, John Sondek, Qisheng Zhang · 2025 · Journal of Biological Chemistry
Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care
Clement Chung · 2025 · American Journal of Health-System Pharmacy
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression
Shady I. Tantawy, Burcu Aslan, Ganiraju C. Manyam, LaKesla R. Iles, Natalia Timofeeva, Neetu Singh, Nitin Jain, Alessandra Ferrajoli, Philip A. Thompson, Keyur Pravinchandra Patel et al. · 2025 · Blood Cancer Journal
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Jorge Julio Castillo, Shayna Sarosiek, Catherine A. Flynn, Carly R. Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven Peter Treon · 2022 · eJHaem
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia
Shih‐Shih Chen, Nicholas Chiorazzi · 2023 · Hematological Oncology
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia
Alycia Hatashima, Mazyar S. Shadman · 2024 · Expert Review of Hematology
Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation
Lone Schejbel, Marie Fredslund Breinholt, Anne Ortved Gang, Torsten Holm Nielsen, Lars Møller Pedersen, Estrid Vilma Solyom Høgdall, Peter H. Nørgaard · 2022 · eJHaem
PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target
Qingyu Luo, Anne Fortune, Andrew A. Lane · 2025 · Blood
Resistance to Bruton Tyrosine Kinase Inhibitors
Jennifer R. Brown · 2025 · Hematology/Oncology Clinics of North America
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Britten K. Gordon, Elizabeth M. Muhowski, Jyotsna Singh, Janani Ravikrishnan, Arnau Peris-Cuesta, Daisy Diaz Rohena, John R. Sanchez, Shanmugapriya Thangavadivel, Samon Benrashid, Alexander He et al. · 2025 · Blood Cancer Discovery
Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma
Atsunobu Takeda, Nobuyo Yawata, Koh‐Hei Sonoda · 2025 · Japanese Journal of Ophthalmology
Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting
Philipp von Hundelshausen, Wolfgang Siess, Rundan Duan, Tonika Bohnert, Brian T. Hopkins, Christian Weber · 2026 · Circulation
Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies
Sieun Yang, Jihye Oh, Soo-Yeon Hwang, Jihye Paik, Inah Hwang · 2026 · Drug Resistance Updates
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
Joachim Rudolph, Klaus P. Hoeflich, Arvin C. Dar · 2026 · Nature Reviews Drug Discovery
Atomic-level protein–ligand recognition with PBCNet2.0 for probe discovery
Jie Yu, Xia Sheng, Zhehuan Fan, Zhaokun Wang, Duanhua Cao, Yufan Tang, Yongxin Hao, Yingying Zhang, Panpan Shao, Huicong Ma et al. · 2026 · Nature Chemical Biology
Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
Tiana Huynh, Sonia Rodrı́guez, Alexey Valeryevich Danilov · 2024 · Molecular Cancer Therapeutics
Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations
Zunyuan Wang, Shu Wang, Youkun Kang, Xinglong Chi, Youlu Pan, Shenxin Zeng, Chixiao Zhang, Xiangwei Xu, Wenyong Wang, Wenhai Huang · 2024 · Chemico-Biological Interactions
Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial
Yanyan Liu, Ningjing Lin, Shuhua Yi, Huiqiang Huang, Ye Guo, Qingyuan Zhang, Haiyan Yang, Huilai Zhang, Liling Zhang, Ru Feng et al. · 2025 · International Journal of Cancer
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis
Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang et al. · 2023 · Leukemia & lymphoma/Leukemia and lymphoma
Approach to relapsed CLL including Richter Transformation
John Francis Seymour · 2023 · Hematological Oncology
Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study
Dai Maruyama, Chaochen Wang, Yoshinori Tanizawa, Zhihong Cai, Yu‐Jing Huang, Masaomi Tajimi, Shigeru Kusumoto · 2023 · Journal of the Japan Society of the Reticuloendothelial System
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024
Andrew Ip, Alexandra Della Pia, Andre Henri Goy · 2024 · Clinical Lymphoma Myeloma & Leukemia
Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia
Manabu Hayama, John Charles Riches · 2024 · OncoTargets and Therapy
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia
Shayna Sarosiek, David J. Sermer, Andrew Robert Branagan, Steven Peter Treon, Jorge Julio Castillo · 2022 · Expert Review of Anticancer Therapy
HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia
Wancheng Guo, Daomiao Liang, Peilong Wang, Le Yin, Huifang Zhang, Xing Cheng, Zineng Huang, Yinghua Wu, Heng Li, Zhao Cheng et al. · 2022 · Pharmaceuticals
SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia
Bita Fakhri, Alexey Valeryevich Danilov · 2023 · Clinical Lymphoma Myeloma & Leukemia
The cat-and-mouse game of BTK inhibition
Ana Portelinha, Hans‐Guido Wendel · 2023 · Blood
Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases
Pei Lin, Dandan Zhang, Jun Lin · 2023 · Current Topics in Medicinal Chemistry
Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Allison Kagerer, Meghan C. Thompson · 2025 · Hematology/Oncology Clinics of North America
Bruton’s Tyrosine Kinase Inhibitors: A Versatile Therapeutic Approach for Cancer, Autoimmune Disorders, GVHD and COVID-19
Swati Paliwal, Uma Agarwal, Rajiv Kumar Tonk · 2025 · Mini-Reviews in Medicinal Chemistry
Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies
Edoardo Tamellini, Cristina Frusteri, Isacco Ferrarini · 2025 · Cell Death and Disease
Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
Emigdio Álvarez-Corrales, Rocío Moreno-Palomares, Carmen Gómez‐Escolar, Mario Martínez‐Mingo, Udane Moral-Pérez, María Laguna-Herrero, Teresa Fuertes, Belén S. Estrada, Sonia M. Mur, Adriana de Bonis et al. · 2026 · Leukemia
A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignancies
Niina Veitonmäki, Anna Kostyn, Sonia Kołt, Aleksandra Ziemblicka, Beata Romanowska, Sabina Oleksy, Ewelina Krzywińska, Kamilla Sołtys, Łukasz Świderski, Piotr Naporowski et al. · 2025 · Frontiers in Immunology
Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs
S Wang, Yuran Qiu, Weili Zhao · 2026 · Chinese Medical Journal
B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting
Yin Zhu, Lu Gao, Yu Han, Fu-Cai Liu, Xin Xie, Xin Dai, Yufeng Wang, Yi-Min Guo, Chunyu Luo, Yan Chen et al. · 2026 · Frontiers in Immunology
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective
Mathias Castonguay, Mary Ann Anderson, Philip A. Thompson, John Francis Seymour · 2026 · Blood Advances
Covalent Radiopharmaceuticals: Precision Imaging and Therapy for Cancer
Paul C. Klauser, Lei Wang · 2026 · Molecular Pharmaceutics
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis
Jeffrey Lambe, Robert James Fox · 2026 · Drugs
Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Jacqueline Wang, Yucai Wang · 2024 · Expert Review of Hematology
Improving Treatment Options for Patients with Double Refractory CLL
Ryan W. Jacobs, William Wierda · 2025 · Cancers
Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?
Elżbieta Iskierka‐Jazdzewska, Bartosz Puła, Krzysztof Jamroziak, Tadeusz Robak · 2025 · Expert Opinion on Investigational Drugs
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Raji E. Joseph, Thomas E. Wales, Sandrine Jayne, Robert G. Britton, D. Bruce Fulton, John R. Engen, Martin J.S. Dyer, Amy Hamilton Andreotti · 2024 · eLife
SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation
John M. Burke · 2022 · Clinical Lymphoma Myeloma & Leukemia
Inhibiting BTK in Chronic Lymphocytic Leukemia
Arnon Philip Kater, Barbara F. Eichhorst · 2023 · New England Journal of Medicine
Advancing Ligand Binding Affinity Prediction with Cartesian Tensor-Based Deep Learning
Jie Yu, Xia Sheng, Zhehuan Fan, Zhaokun Wang, Duanhua Cao, Yongxin Hao, Yingying Zhang, Panpan Shao, Huicong Ma, Tian Cao et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Pirtobrutinib: The Next Generation of Bruton Tyrosine Kinase Inhibitor for Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Prioty Islam, Saad Z. Usmani · 2023 · The Hematologist
Cost–effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients
Jing Nie, Huina Wu, Qian Vicky Wu, Qi Liu, Lihui Liu, Jiyong Wu · 2023 · Future Oncology
Advancing proteolysis targeting chimeras toward clinical drug developments
Xinjian Tian, Chaoqun Huang, Lin Yin, Xufen Yu · 2024 · Elsevier eBooks